Company Profile · Healthcare

Stryker Corporation

SYK · US
Exchange
US
Country
USA
IPO date
Feb 1, 1988
Employees
56,000
Current Price
$307.8
Live · Jun 18, 2026
Fair Buy
≤ $230
Margin-of-safety entry
Baillie Growth Score
49/100
Weak
Intrinsic Value · Three-Tier Range Current price $307.8 Live · Between the fair and optimistic ranges

Composite valuation range · conservative $170–$205 / fair $230–$300 / optimistic $310–$360. At $307.8, Between the fair and optimistic ranges.

At publication $316.48 (May 25, 2026)

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Market cap$115.45B
Revenue (TTM)$25.27B
EBITDA$6.92B
Profit margin13.21%
ROE15.2%
P/E (TTM)34.89
Forward P/E20.08
PEG1.43
EPS$8.63
Dividend yield1.11%
52-week range$281.00 – $401.86
Analyst target$386.80
Analyst rating4.1 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.